Hudson Announces Werner Maas as New Chief Executive Officer
Hudson, a prominent provider of laboratory automation solutions, has appointed Werner Maas as its new Chief Executive Officer. With a rich background in the life science tools sector, Maas brings a wealth of experience focused on fostering innovation, driving scale, and leading organizations through transformational growth. His previous role as President of the Global Liquid Handling business at Mettler Toledo showcases his capability to lead multifaceted business units, where he managed the Rainin and Biotix divisions.
Significant Experience in Life Sciences
Before his successful tenure at Mettler Toledo, Maas held the position of President of the Magnetic Resonance division for the Bruker Biospin Group, where he contributed significantly to the development and distribution of high-performance scientific instruments. His extensive background with notable life science organizations positions him uniquely to steer Hudson towards its ambitious goals.
Looking Forward to the Future
Expressing his enthusiasm about joining Hudson, Maas stated, "Hudson is known for its innovative solutions and deep product portfolio, providing scientists the means to reach higher productivity and reproducible results. I look forward to working with the entire team to build on the company’s strong foundation and help accelerate its success across all markets." His vision aligns with Hudson's commitment to continuous improvement and innovation, which are critical in today’s fast-paced market.
Strengthening Leadership and Focus
As part of this leadership transition, Andrew Witschi will assume a new role as President of Hudson Robotics and Head of Technology. Under his guidance, Hudson Robotics will maintain its focus on delivering top-tier automation solutions to clients, which is essential for advancing life sciences with a firm commitment to quality, reliability, and innovation.
Company Overview
Hudson was formed through the merger of Hudson Robotics, Art Robbins Instruments, and Tomtec, and is headquartered in Springfield, New Jersey. The company specializes in designing, assembling, and integrating liquid handling systems, microplate automation, laboratory robotics, and customized software-driven solutions. Hudson’s offerings play a crucial role in drug discovery, clinical research, protein crystallization, high-throughput experimentation, and pharmaceutical development with a strong emphasis on the pharma, biopharma, academic, and OEM markets.
About Argosy Healthcare Partners
Argosy Healthcare Partners is a private equity firm dedicated to healthcare, focusing on founder-owned companies across the United States. With an impressive portfolio, Argosy aims to support the growth of businesses that generate between $1.0 to $3.0 million in EBITDA. Their strategy involves majority control transactions that respect and bolster the existing company culture while facilitating reinvestment and acceleration of growth.
Frequently Asked Questions
Who is the new CEO of Hudson?
The new CEO of Hudson is Werner Maas, who brings extensive experience in the life sciences sector.
What role did Werner Maas have before joining Hudson?
Before joining Hudson, Werner Maas was the President of the Global Liquid Handling business at Mettler Toledo, managing various business units.
What is Hudson known for?
Hudson is known for its innovative laboratory automation solutions and comprehensive product portfolio that enhances scientific productivity.
What will Andrew Witschi's new role be?
Andrew Witschi will take on the role of President of Hudson Robotics and Head of Technology, focusing on delivering advanced automation solutions.
What is the focus of Argosy Healthcare Partners?
Argosy Healthcare Partners focuses on supporting founder-owned healthcare businesses and facilitating their growth through strategic investments.
